CPI-818, an oral interleukin-2-inducible T-cell kinase inhibitor, is well-tolerated and active in patients with T-cell lymphoma Meeting Abstract
| Authors: | Khodadoust, M. S.; Feldman, T. A.; Yoon, D. H.; Yannakou, C. K.; Radeski, D.; Kim, Y. H.; Mehta-Shah, N.; Khot, A.; Wilcox, R. A.; Kim, W. S.; Horwitz, S. M.; Buggy, J. J.; Hotson, A.; Hill, C. M.; Munneke, B.; Mahabhashyam, S.; Miller, R. A.; Janc, J. W.; Mobasher, M. |
| Abstract Title: | CPI-818, an oral interleukin-2-inducible T-cell kinase inhibitor, is well-tolerated and active in patients with T-cell lymphoma |
| Meeting Title: | 62nd Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 136 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2020 Dec 5-8 |
| Meeting Location: | Virtual |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2020-11-05 |
| Language: | English |
| ACCESSION: | WOS:000607205605166 |
| DOI: | 10.1182/blood-2020-137782 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 19 -- Source: Wos |
